RxDoctor Payments Data

Tara Stock, DO

Family Medicine · Wellington, FLNPI 1639193568

Payments from drug & device makers

$3,224in general payments, 2019–2025

Across 198 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$477
  • AstraZeneca$391
  • Boehringer Ingelheim$352
  • AbbVie$301
  • GSK$245
  • Amarin Pharma, Inc.$207
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$3,209100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,224 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$73,107
Medicare patients
264
Services billed
1,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin100$95,257
EliquisApixaban83$67,962
OzempicSemaglutide33$30,325
MounjaroTirzepatide28$26,997
XareltoRivaroxaban16$18,632
VascepaIcosapent Ethyl13$9,481
Breo ElliptaFluticasone/Vilanterol13$5,800
Fluticasone-SalmeterolFluticasone Propion/Salmeterol39$4,747
Wixela InhubFluticasone Propion/Salmeterol15$2,461
Rosuvastatin Calcium283$2,232
Albuterol Sulfate HfaAlbuterol Sulfate99$2,219
Atorvastatin Calcium248$2,084
Levothyroxine Sodium254$1,994
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,850
Valsartan63$1,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$352$95,257100 claims
PfizerEliquis$164$67,96283 claims
Novo NordiskOzempic$477$30,32533 claims
Lilly USA, LLCMounjaro$16$26,99728 claims
Johnson & JohnsonXarelto$29$18,63216 claims
GSKBreo Ellipta$245$5,80013 claims
AbbVieSynthroid$301$1,06811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Wellington

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →